Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.23 USD | -1.70% | -0.44% | 0.00% |
Apr. 22 | Guggenheim Starts Coverage on Boundless Bio With Buy Rating, $24 Price Target | MT |
Apr. 22 | Piper Sandler Starts Audentes Therapeutics With Overweight Rating, $20 Price Target | MT |
Valuation
Fiscal Period: December | 2024 | 2025 | 2026 |
---|---|---|---|
Capitalization 1 | 209 | - | - |
Enterprise Value (EV) 1 | 178.2 | 172.7 | 107.8 |
P/E ratio | -1.23 x | -2.23 x | -2.1 x |
Yield | - | - | - |
Capitalization / Revenue | - | - | - |
EV / Revenue | - | - | - |
EV / EBITDA | -2.45 x | -1.58 x | -0.69 x |
EV / FCF | -3.3 x | -2.47 x | -1.21 x |
FCF Yield | -30.3% | -40.5% | -82.6% |
Price to Book | - | - | - |
Nbr of stocks (in thousands) | 22,253 | - | - |
Reference price 2 | 9.390 | 9.390 | 9.390 |
Announcement Date | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Net sales 1 | - | - | - | - |
EBITDA 1 | - | -72.68 | -109 | -156.4 |
EBIT 1 | - | -75.18 | -102.3 | -129.2 |
Operating Margin | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -71.15 | -94.83 | -114.3 |
Net income 1 | -49.43 | -69.23 | -96.79 | -127.3 |
Net margin | - | - | - | - |
EPS 2 | -2.080 | -7.643 | -4.217 | -4.477 |
Free Cash Flow 1 | - | -54 | -70 | -89 |
FCF margin | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - |
Dividend per Share 2 | - | - | - | - |
Announcement Date | 3/6/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - |
EBIT 1 | -16.88 | -18.25 | -19.53 | -20.51 | -22.83 | -23.75 |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -15.43 | -17.58 | -18.44 | -19.72 | -21.13 | -22.81 |
Net income 1 | -15.43 | -17.45 | -18.36 | -19.58 | -21.13 | -22.81 |
Net margin | - | - | - | - | - | - |
EPS 2 | -12.27 | -0.7967 | -0.8167 | -0.8633 | -0.9400 | -1.015 |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 5/13/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Net Debt 1 | - | - | - | - |
Net Cash position 1 | - | 30.7 | 36.3 | 101 |
Leverage (Debt/EBITDA) | - | - | - | - |
Free Cash Flow 1 | - | -54 | -70 | -89 |
ROE (net income / shareholders' equity) | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - |
Assets 1 | - | - | - | - |
Book Value Per Share | - | - | - | - |
Cash Flow per Share | - | - | - | - |
Capex 1 | - | 0.4 | 0.5 | 0.5 |
Capex / Sales | - | - | - | - |
Announcement Date | 3/6/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 209M | |
+18.60% | 125B | |
+14.98% | 108B | |
-6.13% | 23.64B | |
+2.39% | 22.39B | |
-12.11% | 17.78B | |
-41.64% | 16.43B | |
-12.95% | 16.34B | |
+0.93% | 13.56B | |
+25.90% | 11.59B |
- Stock Market
- Equities
- BOLD Stock
- Financials Boundless Bio, Inc.